19.22
-0.14(-0.72%)
Currency In USD
| Previous Close | 19.36 |
| Open | 19.35 |
| Day High | 19.36 |
| Day Low | 18.97 |
| 52-Week High | 22.5 |
| 52-Week Low | 8.18 |
| Volume | 235,853 |
| Average Volume | 1.8M |
| Market Cap | 1.48B |
| PE | -6.47 |
| EPS | -2.97 |
| Moving Average 50 Days | 14.91 |
| Moving Average 200 Days | 11.81 |
| Change | -0.14 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $1,011.05 as of December 26, 2025 at a share price of $19.22. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $1,949.29 as of December 26, 2025 at a share price of $19.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-fr
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
GlobeNewswire Inc.
Dec 06, 2025 2:30 PM GMT
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology a